Navigate Up
Sign In


For the fifth time in succession the biopharmaceutical research company MSD, which is developing drugs and vaccines, has been awarded the label “Top Employer Switzerland” and for the second time also the label “Top Employer Europe.” Learn more​.

World Immunization Week starts on April 24. The #vaccineswork campaign aims to raises awareness of the importance of vaccination and the WHO's global vaccination plan, known as the Global Vaccine Action Plan or GVAP. Immunization saves millions of human lives and is generally recognized as the most successful and cost-effective health intervention. Today there are still 19.4 million unvaccinated or inadequately vaccinated children around the world. MSD is supporting the #vaccineswork campaign. It gives us the opportunity to highlight the success of immunization as a preventative measure against illnesses and suffering around the world. We also remain committed to improving vaccine protection for people of any age and to improving access to our vaccines globally. #vaccineswork. Learn more.​​

4 February 2017 is World Cancer Day. Today, the focus worldwide is on the prevention, research and treatment of cancer. MSD supports the action day initiated by the World Cancer Organization UICC and has become a formal sponsor for 2017 and 2018.
 Learn more.​​

​MSD in Switzerland

MSD (known as Merck & Co., Inc., Kenilworth, NJ, USA in the United States and Canada) is one of the world's leading healthcare companies with its headquarters in the United States. In Switzerland, MSD is one of the most important pharmaceutical research companies. From our base at Lucerne we serve the Swiss healthcare market and support more than 70 subsidiaries across Europe, Canada, the Middle East, Africa, Brazil, India, and China. Welcome to MSD.

MSD as an employer 

To achieve our ambitious goals, we need the best possible specialist staff and highly committed employees. We offer various positions in a wide range of business areas like for example within our local and international sales organizations, research & development, manufacturing, and within the core departments of our global business located in Lucerne.
Find out more​


​MSD is reintegrating vaccines into its portfolio​

At the end of December 2016, Sanofi Pasteur and MSD terminated their vaccine joint venture SPMSD. SPMSD has been responsible for access to important vaccines in 19 European countries for more than 20 years and has helped significantly to support the high-quality provision of vaccines in Switzerland. Numerous new vaccines from the pipelines of Sanofi Pasteur and MSD have helped during this time to protect millions of human lives.
As of January 1, 2017, MSD has reintegrated the vaccines portfolio and is managing the portfolio independently. MSD has been investing in research and development of new and improved vaccines for more than 100 years and has a product portfolio to protect children, adolescents and adults.

General Remark:

Please be aware of the fact that each time when using one of the links in this website, you are leaving the Merck Sharp & Dohme AG, Switzerland (MSD), website and thus our sphere of responsibility. The linked Internet pages have their own terms of use and may be subject to different laws and standards.​​